Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experience

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1447-1453

  Ratnam, Dilip ^a,b   Dev, Anouk ^a,b   Nguyen, Tin ^c   Sundararajan, Vijaya ^b   Harley, Hugh ^d   Cheng, Wendy ^e   Lee, Alice ^f   Rusli, Ferry ^a   Chen, Robert ^c   Bell, Sally ^c   Pianko, Stephen ^a   Sievert, William ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

^f ANZAC Research Institute   (Australia)

Author keywords

Anitviral therapy; Hepatitis B; Pegylated interferon; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBIMAZOLE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERTHYROIDISM; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84865355778     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07051.x     Document Type: Article

References (37)

1. World Health Organization. Hepatitis B. Fact sheet 204. Cited Aug 2008. Available from URL: http://wwwwhoint/mediacentre/factsheets/fs204/en/2008.
2. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
3. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
4. Niederau C, Heintges T, Lange S etal. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 1422-7.
5. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J. Hepatol. 2001; 34: 306-13.
6. van Zonneveld M, Honkoop P, Hansen BE etal. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-10.
7. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-95.
8. Bedossa P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
10. Lok ASF, McMahon BJ. Chronic hepatitis B (AASLD Practice Guidelines). Cited 10 Apr 2010. Available from URL: http://wwwaasldorg 2009.
11. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
12. Janssen HL, van Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
13. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10: 298-305.
14. Chan HL, Leung NW, Hui AY etal. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann. Intern. Med. 2005; 142: 240-50.
15. Zhao H, Kurbanov F, Wan MB etal. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin. Infect. Dis. 2007; 44: 541-8.
16. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
17. Hsu YS, Chien RN, Yeh CT etal. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-7.
18. Yang HI, Lu SN, Liaw YF etal. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med. 2002; 347: 168-74.
19. Marcellin P, Lau GK, Bonino F etal. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004; 351: 1206-17.
20. Rijckborst V, ter Borg MJ, Cakaloglu Y etal. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am. J. Gastroenterol. 2010; 105: 1762-9.
21. Buster EH, Flink HJ, Cakaloglu Y etal. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
22. Marcellin P, Bonino F, Lau GK etal. Sustained response of hepatitis B e antigen-negative patients 3years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-79.
23. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338-42.
24. Moucari R, Korevaar A, Lada O etal. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J. Hepatol. 2009; 50: 1084-92.
25. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 1991; 114: 629-34.
26. Perrillo RP, Schiff ER, Davis GL etal. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990; 323: 295-301.
27. Lau DT, Everhart J, Kleiner DE etal. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-7.
28. Marcellin P, Lau GK, Zeuzem S etal. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. Liver Int. 2008; 28: 477-85.
29. Bonino F, Marcellin P, Lau GK etal. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705.
30. Flink HJ, Hansen BE, Heathcote EJ etal. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am. J. Gastroenterol. 2006; 101: 2523-9.
31. Buster EH, Hansen BE, Lau GK etal. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-9.
32. Lau G, Marcellin P, Brunetto M etal. On-treatment HBsAg decline during peginterferon alfa-2a (40kd)±lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response. Hepatology 2008; 48: 714A.
33. Brunetto MR, Moriconi F, Bonino F etal. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
34. Moucari R, Mackiewicz V, Lada O etal. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
35. Fried MW, Piratvisuth T, Lau GK etal. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
36. Rijckborst V, Hansen BE, Cakaloglu Y etal. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52: 454-61.
37. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52: 1251-7.